Kornimate/medical-research-clean huggingface dataset:
effect of c1-esterase inhibitor on systemic inflammation in trauma patients with a femur or pelvic fracture

Conditions: Trauma; Inflammation; Sepsis; Multiple Organ Dysfunction Syndrome

Summary: trauma and major operation are associated with an excessive inflammation reaction due to tissue injury. this overwhelming immune response is considered to be a major risk factor in the pathogenesis of late inflammatory complications such as acute respiratory distress syndrome (ards), multiple organ dysfunction syndrome (mods) and sepsis. the investigators hypothesize that administration of c1-esterase inhibitor (c1-inh) will attenuate the humane inflammatory response and, thereby, reduce the risk of inflammatory complications due to surgical interventions in trauma patients with a femur or pelvic fracture

systemic inflammation in response to a femur or pelvic fracture and fixation is associated with complications, such as acute respiratory distress syndrome (ards) and multiple organ dysfunction syndrome (mods). the injury itself, but also the additional fixation procedure give a release of pro-inflammatory cytokines, in particular interleukin (il)-6. this results in an aggravation of the initial systemic inflammatory response, and will cause in some patients an increased risk on the development of inflammatory complications, like ards and mods. which can lead to higher morbidity, mortality and prolonged hospital stay. various strategies, such as damage control orthopedics, have been proposed to prevent these complications. another strategy is to decrease the inflammatory reaction caused by the surgical procedure, and by interventions focused on inhibition of the innate inflammatory response. this will lower the risk of complications. a promising candidate is the endogenously produced serum protein c1-esterase inhibitor (c1-inh). this protein is an acute phase protein, produced by the liver in response to inflammatory conditions. c1-inh is a major inactivator of the complement system, but important additional anti-inflammatory properties have been demonstrated. a previous study of from our laboratory showed that administration of the drug c1-inh significantly reduced the concentration of circulating pro-inflammatory cytokines such as il-6, during human experimental endotoxemia. treatment with c1-inh has been proven to be safe in treatment with humans, even in high dosages and in pregnant patients with c1-inh deficiency.

Eligibility criteria:
inclusion criteria: * multi trauma patients * femur or pelvic fracture * injury severity score (iss) ≥ 18 * age 18-80 yrs exclusion criteria: * congenital c1-inhibitor deficiency * use of immune suppressants * pregnancy * known hypersensitivity for blood products * fixation of femur fracture with external fixation or osteosynthesis

Keywords: c1-esterase inhibitor systemic inflammation sepsis trauma multiple organ dysfunction syndrome cytokines
tranexamic acid for the prevention of postpartum hemorrhage in pregnant women with placenta previa

Conditions: Hemorrhage, Postpartum; Placenta Previa

Summary: many rct(randomized controlled trial) studies reported that tranexamic acid reduced blood loss in women who had elective cesareans. however, most of these elective cesareans are without high-risk factors of postpartum hemorrhage, such as placenta previa. the prophylactic use of tranexamic acid in the placenta previa is not clear. studies had poor quality and lacked adequate power to assess severe adverse events.


Eligibility criteria:
inclusion criteria: * age of 18 years or older * diagnosed with placenta previa before cesarean delivery by ultrasound（placenta previa defined by a placental edge below 20mm from internal cervical os diagnosed at the most recent transvaginal ultrasound examination before delivery） * gestational age ≥ 34 weeks * available venous hematocrit value in the week before the cesarean * prenatal hemoglobin level in the week before the cesarean \> 90 g/l * undergoing cesarean delivery * signed informed consent exclusion criteria: * known hypersensitivity to tranexamic acid or concentrated hydrochloric acid * history of venous (deep vein thrombosis and/or pulmonary embolism) or arterial thrombosis (angina pectoris, myocardial infarction, or stroke) * history of epilepsy or seizure * any known active cancer, active cardiovascular, renal, or liver disorders * autoimmune diseases such as lupus, rheumatoid arthritis, sjogren's disease, and inflammatory bowel disease * sickle cell disease * severe hemorrhagic disease * administration of low-molecular-weight heparin or antiplatelet agents within one week prior to delivery * severe coagulation disorders with prothrombin time or activated partial thromboplastin time exceeding the upper limit of normal, or platelet count less than 80×109/l * placenta abruption * in-utero fetal death * eclampsia or hellp syndrome * acquired color vision deficiency or subarachnoid hemorrhage * severe bleeding with estimated blood loss exceeding 500 ml, within 12 hours before cesarean delivery * known congenital or acquired thrombophilias, including antiphospholipid antibody syndrome * participation in another intervention study where the primary outcome includes postpartum bleeding or thromboembolism or the study intervention potentially affects postpartum bleeding or thromboembolism
anti-fat attitudes and weight stigma among orthopedic surgeons

Conditions: Weight Stigma

Summary: evidence shows that anti-fat attitudes and weight stigma are prevalent among healthcare professionals and may affect treatment decisions regarding patients with obesity. the present study aimed to examine the presence of anti-fat attitudes and weight stigma among orthopedic surgeons and their correlation to the therapeutic approach to patients with obesity. in this cross-sectional survey, 150 orthopedic surgeons will complete a web-based questionnaire. the questionnaire is based on antifat attitudes questionnaire (afa), developed by crandall in 1994. in addition, the questionnaire will include a questionnaire developed by bocquier in 200521 to explore weight stigma among physicians.

data will be collected through an online questionnaire consisting of four parts. part 1 will gather socio-demographic data using nine items. part 2 will utilize the antifat attitudes questionnaire (afa), developed by crandall in 1994. the questionnaire, comprising 13 items, will assess three subscales:1. "dislike" measuring explicit antipathy toward fat individuals.2. "fear of fat" measuring personal concerns about weight or becoming overweight.3. "willpower" measuring beliefs about personal control over being overweight. participants will rate items on a 10-point likert scale, with higher scores indicating greater anti-fat bias. part 3 will include a questionnaire developed by bocquier in 2005 to explore weight stigma among physicians, consisting of 12 items. participants will rate items on a 6-point likert scale, with higher scores indicating stronger weight stigma. part 4 will investigate the therapeutic approach of orthopedic surgeons to patients with obesity using five items. participants will items on a 6-point likert scale, with higher scores indicating a stronger preference for a conservative approach.

Eligibility criteria:
inclusion criteria: orthopedic surgeon age 18 till 80 - exclusion criteria: -
caffeine, resistance exercise and muscle/cerebral oxygenation

Conditions: Caffeine and Resistance Exercise

Summary: introduction: several studies have evaluated and confirmed the ergogenic effects of acute caffeine intake on sports performance. however, the mechanism responsible for this ergogenic effect remains to be elucidated. objectives: this study aims to evaluate the acute effects of caffeine intake on muscle and cerebral oxygen during muscular strength, power, muscle endurance performance. and muscle electrical activity in young adults.


Eligibility criteria:
inclusion criteria: * age between 18 and 35 years. * body mass index (bmi) \&lt; 25 kg/m². * resistance-trained individuals (more than 2 years of structured training). * healthy men and women without neurological, cardiometabolic, immunological, or physical conditions that prevent them from exercising. * participants must be able to perform the tests described in the following section. exclusion criteria: * history of neuromuscular diseases, heart disease, or conditions that may affect liver or muscle metabolism. * use of drugs, stimulants, or sports supplements that could interfere with the dietary supplement used in the study. * sedentary habits (less than 150 minutes/week of moderate exercise). * having undergone prolonged periods of physical inactivity in the 6 months prior to the study. * engaging in strenuous exercise within 48 hours prior to the tests. * failure to replicate the same food intake on both experimental days. * consumption of caffeine or any other stimulant after 6 pm on the day before the tests, to avoid headaches, discomfort, or lethargy in regular caffeine consumers.
effects of liraglutide on kidney function in type 2 diabetic patients

Conditions: Type 2 Diabetes Mellitus

Summary: recent studies in rodents show that glucagon-like peptide-1 (glp-1) analogues protect against diabetic nephropathy. we hypothesise that this is also the case in humans. this study will investigate the short-term effect of liraglutide (glp-1 analogue) on the kidneys in type 2 diabetic patients. impact on basic kidney physiological will be determined and kidney injury markers will be measured as surrogate parameters of kidney protection.


Eligibility criteria:
inclusion criteria: * informed consent obtained before any trial-related activities. * male gender * t2dm, diagnosed according to international guidelines * age 20-60 years, both included * body mass index (bmi): 20-32 kg/m2, both included * metformin treatment * albumin/creatinine ratio \<25 mg/mmol exclusion criteria: * known or suspected allergy to trial product or related products * previous participation in this trial * previous treatment with glp-1 analogues or dpp-4 inhibitors * current treatment with any antidiabetic drug other than metformin * poorly regulated glycemic control (hba1c \> 8%) * impaired kidney function: estimated gfr \< 70ml/min * impaired liver function: liver parameters exceed 2 times upper normal limit * subjects with active malignancy * severe cardiac insufficiency classified according to nyha iii-iv * unstable angina pectoris, acute myocardial infarction (ami) within the last 12 months * severe, uncontrolled hypertension: sitting blood pressure (bp) \> 180/110 mmhg * antihypertensive treatment consisting of more than two different pharmaceutical products * symptoms related to benign prostate hyperplasia * claustrophobia * any metal body implants * history of pancreatitis, type 1 diabetes, gastroparesis or multiple endocrine neoplasia syndrome type 2 * personal or family history of medullary thyroid carcinoma * any diseases judged by the investigator that could affect the trial * any medication judged by the investigator that could affect the trial

Keywords: liraglutide victoza glp-1 kidney diabetes renal diabetic nephropathy
beat af - braking ectopic atrial trends in atrial fibrillation

Conditions: Paroxysmal Atrial Fibrillation

Summary: paroxysmal af subjects with a documented ecg event of af will be recruited to the study to assess the efficacy of cardiacare™ rr2 wearable home-care neuromodulation system in reducing af burden and symptoms in paroxysmal af patients

after screening for 14 days with a continuous ecg monitoring device, eligible patients will be randomized to either active treatment or a sham treatment groups. for a treatment period of 12 weeks, patients will be prompted to self-conduct neuromodulation sessions based on: a. predetermined treatment regimen plus b. a detection algorithm. in addition, participants will measure at home, daily 2 min ecg's with the rr2 system two times a day and when feeling symptoms suspected as af/at/svt or pac's. after 10 weeks of treatment patients will be requested to wear an ecg patch continuously for an additional period of 14 days. overall patients will participate in the study for 14 weeks.

Eligibility criteria:
inclusion criteria: * men and women ages 18-85 years with history of documented paroxysmal (\<7 days) atrial fibrillation * af burden (% time in af) of more than 0.5% and less than 25% as evident by a continuous 14 days ecg recording at baseline (at minimum 168 hours) * ability and willingness to sign an informed consent form * ability and willingness to use cardiacare home care device and ecg chest patch and has an available smart phone * known symptomatic af event over the recent 3 months * willing not to change the antiarrhythmic treatment exclusion criteria: * hemodynamic instability (systolic blood pressure \ 170 bpm at baseline) during recruitment visit * known history or current diagnosis of atrial flutter * an active myocardial infarction evident from ecg * recent stroke or myocardial infarction (\<6 months) * history of sick sinus syndrome 2nd or 3rd degree av block, bifascicular block or prolonged (pr\>300ms) 1st degree av block * unilateral or bilateral vagotomy * history of persistent af with documented af episodes of \>7 days * significant valvular disorder (i.e., prosthetic valve or hemodynamically relevant valvular diseases or valvular af) * history of impaired systolic function with ef\<40 % or ny class iii or iv heart failure classification * dilatated left atria with a diameter \> 50mm as evident by an echocardiogram * currently enrolled in another study * recurrent vaso-vagal syncopal episodes * pregnancy or breast feeding * pacemaker or crtd or any implanted electrical stimulating device * history of epilepsy or seizures * peripheral neuropathy or dermatological condition affecting the tested upper extremity area * unsuitable for participating in the study according to attending physician
study of the pathogenicity and humoral immune response induced by bk virus in lung transplant recipients

Conditions: Renal-urinary Impairment; Graft Rejection; Infection Episodes

Summary: bk virus (bkv) is a ubiquitous virus that infects more than 80% of the population. in case of immunosuppression, bkv can replicate and induce nephropathies in renal transplant recipients or haemorrhagic cystitis in bone marrow transplant recipients. the disruption of the balance between bkv replication and immune control is considered the key element in the development of these pathologies. during lung transplantation, patients undergo intense immunosuppression that favors the reactivation of persistent viruses such as ebv, cmv and probably bkv. although the data on ebv and cmv reactivation are very clear and allow optimal management, the prevalence of bkv replication and its clinical impact in lung transplant recipients remains unknown at this time. the aim of this study is to know the incidence and clinical impact of bkv replication in lung transplant recipients. moreover, the results will help to better understand the interaction between the virus and his host, with a focus on the humoral and cellular immune response against bkv. the results could possibly enable to define predictive markers of bkv replication and of its evolution.


Eligibility criteria:
inclusion criteria: * lung transplant recipients in strasbourg university hospital between 30 june 2018 and 31 december 2022 * male or female patients, age over 18 years * patient having provided informed written consent to take part in the study * patient affiliated to social security exclusion criteria: * patient deprived of liberty, by judicial or administrative decision * patient under legal guardianship * impossibility to give complete information about this study to the patient

Keywords: lung transplantation bkv nephropathy immunosuppression
a study of perioperative ql1706 in participants with untreated dmmr/msi-h resectable colon cancer

Conditions: Colon Cancer

Summary: the goal of this clinical trial is to evaluate the efficacy of perioperative ql1706 in participants with untreated t4n0 or stage iii (resectable), microsatellite instability high/ defective mismatch repair (msi-h/dmmr) colon cancer


Eligibility criteria:
inclusion criteria: * signed written informed consent; * eastern cooperative oncology group performance status of 0 or 1 * untreated pathologically confirmed colon adenocarcinoma * radiographic assessment showed a resectable stage iib-iii based on ajcc stage viii (ct4 or cn+ only). * has a tumor demonstrating the presence of msi-h/ dmmr * adequate organ function as described in the protocol exclusion criteria: * previously received any antitumor therapy for the disease under study, including surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc * has distant metastatic disease. * has an active autoimmune disease that has required systemic treatment in past 2 years * has know history of, or any evidence of interstitial lung disease; * has an active infection requiring systemic therapy
incubation time and test of cure of chlamydia trachomatis

Conditions: Chlamydia Trachomatis Infection

Summary: objective was to understand the dynamics of chlamydia trachomatis (ct) detection by nucleic acid amplification testing (naat) after treatment and consequences for test-of-cure practice.

prospective cohort study on detection of chlamydial ribosomal ribonucleic acid (rrna) and deoxyribonucleic acid (dna) in anorectal and cervicovaginal chlamydia trachomatis (ct) infections during 8 weeks after directly observed treatment with azythromycin. the investigators systematically assessed presence of ct plasmid dna and rrna through multiple time-sequential measurements following treatment with 1000mg azythromycin. by convenience sampling at our outpatient sexually transmitted diseases (std) clinic, 46 non-pregnant women and 6 men were included, contributing 45 cervicovaginal and 15 anorectal infections. over a period of 8 weeks, patients provided a total of 1016 self-taken cervicovaginal and/or anorectal swabs (response: 94%). all patients were negative for human immunodeficiency virus (hiv), gonorrhea and lymphogranuloma venereum (lgv), tested in anorectal ct. usual care was applied by advising abstinence or safe sex for one week and by providing treatment for steady partners. participants provided written informed consent.

Eligibility criteria:
inclusion criteria: * chlamydia trachomatis diagnosis, * age \>=18 years exclusion criteria: * pregnancy, * doxycycline treated-ct, * recent treatment with antibiotics, * co-infections with other std

Keywords: chlamydia trachomatis anorectal cervicovaginal msm women treatment rna bacterial load sexual behaviour azythromycin treated
exercise training in youth with inflammatory bowel disease

Conditions: Pediatric Inflammatory Bowel Diseases; Pediatric Crohns Disease; Pediatric Ulcerative Colitis

Summary: children and adolescents with inflammatory bowel disease (ibd) suffer from many extra-intestinal side effects, including impaired muscle strength, low aerobic fitness, low bone density, and chronic inflammation. while exercise training can help remedy these issues in adults with ibd, no studies have examined the physiological effects of a structured aerobic and resistance exercise training intervention for youth with ibd. the aim of this pilot study is to to assess the feasibility, safety, and participant satisfaction of a structured 16-week training program for children with ibd. the secondary objectives of this study were to quantify the effects of a 16-week exercise training program on select physiological and behavioural outcomes in children with ibd.


Eligibility criteria:
inclusion criteria: * in remission (score of \>10) according to the pediatric crohn's disease activity index (pcdai) or the ulcerative colitis activity index (pucai) * confirmed ibd diagnosis exclusion criteria: * children who exercise train 3 times a week of more
superior capsular reconstruction versus. partial repair for irreparable rotator cuff tears

Conditions: Rotator Cuff Tears

Summary: rotator cuff tear is one of the common injuries that cause shoulder pain in the elderly. after the rotator cuff tendon is injured, repairing the torn rotator cuff tendon through arthroscopic surgery is an effective treatment that is currently widely used. in the rotator cuff injury, irreparable rotator cuff injury is a difficult point in treatment, especially for patients with a long injury time, the obvious shrinkage of the injured tendon, muscle atrophy and steatosis may occur, all of which lead to the poor quality of the rotator cuff tendon needed to be repaired , poor healing ability, seriously affecting the shoulder joint function and daily life of these patients. for this part of patients, arthroscopic partial repair of torn rotator cuffs is one of the commonly used methods. in addition, in recent years, superior capsular reconstruction has been gradually applied to the clinic and has achieved good clinical effects, but there are no controlled studies to compare clinical effect of partial repair and superior capsular reconstruction on irreparable rotator cuff injury.


Eligibility criteria:
inclusion criteria: * patients with irreparable rotator cuff tears * underwent superior capsular reconstruction or partial repair * at least two years follow-up exclusion criteria: * reparable rotator cuff tears * underwent reverse total shoulder arthroplasty

Keywords: irreparable rotator cuff tears superior capsular reconstruction
short term outcomes of children with acute respiratory distress syndrome

Conditions: Acute Respiratory Distress Syndrome

Summary: the study is a chart review of all children admitted over a two year period with the diagnosis of acute respiratory distress syndrome. short term outcomes, such as mortality, length of ventilation and length of stay, will be reviewed. factors that impact these outcomes will also be reviewed.

we would like to conduct a chart review of all patients with pediatric ards hospitalized in the picu at columbus children's hospital in the last two years. patients would be included for review if they met the clinical criteria for ards. these criteria are: rapidly progressive respiratory failure, severe hypoxemia (pao2/fio2 \< 200), and evidence of bilateral pulmonary infiltrate on chest radiography. we estimate 40-50 patients will meet criteria. once criteria are met, patient charts will be pulled or reviewed electronically. we will then compose a database that includes no patient identifiers but contains information regarding the cause, length, and outcome of the ards admission and picu stay. factors such as nutritional status, antibiotic and muscle relaxant use, and type of ventilation used will be examined. other care-related variables will be included if they are felt to impact outcome during the review process. the database will then be analyzed and information regarding pediatric ards outcomes in our institution will be published. we anticipate that examining the factors that impact short term outcomes in pediatric ards will lead to research possibilities regarding ways to improve both short and long term outcomes in children with this illness. we propose that reviewing the disease entity as a whole will lead to improvements in caring for children with the disease, and eventually bring about a decline in mortality rates.

Eligibility criteria:
inclusion criteria: * rapidly progressive respiratory failure, * severe hypoxemia (pao2/fio2 \< 200), * evidence of bilateral pulmonary infiltrate on chest radiography * 0-18 years of age exclusion criteria: * heart failure * cardiac shunt present